Abstract CT194: First-in-human, phase 1/2 study of GSK4418959, an oral Werner DNA helicase inhibitor, alone or combined with other anticancer agents in adults with advanced mismatch repair-deficient or microsatellite instability-high solid tumors (SYLVER)
Year: 2025
Type: conference-abstract
Source: Cancer Research
Authors: Vivek Samnotra, Natalia Ramos-Hernandez, Thomas Faitg, Meenakshi Srinivasan, Tania Roy, Andrew Liu, Tomasz Zaremba, Clare Holford, Rachel Smith, Jason T. Henry, Jeanne Tie, Noboru Yamamoto, Gul Serbest
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4409822077